REFERENCE

Akagi J., Takai E., Tamori Y., Nakagawa K., Ogawa M. (2001), CA19-9 epitope a possible marker for MUC-1/Y protein, Int. J. Oncol. Vol. 18 (5), 1085-1091.

Akewanlop C., Watanabe M., Singh B., Walker M., Kufe D.W., Hayes D.F. (2001), phagocytosis of breast cancer cells mediated by anti-MUC1 monoclonal antibody, DF3, and its bispecific antibody, Cancer Research, Vol. 61, 4061–4065.

Baruch A., Hartmann M.L., Yoeli M., Adereth Y., Greenstein S., Stadler Y., Skornik Y., Zaretsky J., Smorodinsky N., Keydar I., and Wreschner D.H. (1999), The breast cancer-associated MUC1 gene generates both a receptor and its cognate binding protein. Cancer Research, Vol. 59, 1552–1561.

Baruch A., Hartman M., Zrihan-Licht., Greenstein S., Burstein M., Keydar I., Weiss M., Smorodinsky N., Wreschner D.H. (1997), Preferential expression of novel MUC1 tumor antigen isoforms in human epithelial tumors and their tumor potentiating function, Int. J. Cancer. Vol. 71, 741–749.

Begum M., Karim S., Malik A, Khurshid R., Asif M., Salim A., Nagra S.A., Zaheer A., Iqbal Z., Abuzenadah A.M., Alqahtani M.H., Rasool M. (2012), CA 15-3 (Mucin-1) and physiological characteristics of breast cancer from Lahore, Pakistan. Asian Pacific Journal of Cancer Prevention, Vol. 13, 5257-5261.

Beiki O., Hall P., Ekbom A. and Moradi T. (2012), Breast cancer incidence and case fatality among 4.7 million women in relation to social and ethnic background: a population-based cohort study. Breast Cancer Research, Vol. 14:R5, 1-13.

Blixt O., Bueti D., Burford B., Allen D., Julien S., Hollingsworth M., Gammerman A., Fentiman I., Taylor-Papadimitriou J., Burchell J.M. (2011), Autoantibodies to aberrantly glycosylated MUC1 in early stage breast cancer are associated with a better prognosis. Breast Cancer Research, Vol.13:R25, 1-16.

Cancer Research UK (2012), UK Breast Cancer Incidence Statistics. Retrieved 11.9.2012, from http://info.cancerresearchuk.org/cancerstats/types/ breast/incidence/.

Croce M.V., Isla-Larrain M.T., Rua C.E., Rabassa M.E., Gendler S.J., Segal-Eiras A. (2003), patterns of MUC1 tissue expression defined by an anti-MUC1 cytoplasmic tail monoclonal antibody in breast cancer, The Journal of Histochemistry & Cytochemistry, Vol. 51(6), 781–788.

Daniele A., Divella R., Trerotoli P., Caringella M.E., Paradiso A., Casamassima P., Ines Abbate, Quaranta M. and Mazzocca A. (2013), Clinical usefulness of Cancer antigen 15-3 in breast cancer patients before and after surgery, The Open Breast Cancer Journal, Vol. 5, 1-6.

Duffy MJ. (2001), Biochemical markers in breast cancer: which ones are clinically useful, Clin Biochem, Vol. 34, 347–352.

Duffy M.J., Duggan C., Keane R., Hill A.D.K, McDermott E., Crown J. and Higgins N.O. (2004), High Preoperative CA 15-3 Concentrations Predict Adverse Outcome in Node-Negative and Node-Positive Breast Cancer: Study of 600 Patients with Histologically Confirmed Breast Cancer. Clinical Chemistry, Vol. 50:3, 559–563.

Gion M., Mione R., Leon A.E., and Dittadi R. (1999), Comparison of the diagnostic accuracy of CA27.29 and CA15.3 in primary breast cancer. Clinical Chemistry, Vol. 45 (5), 630–637.

Greenlee RT, Hill-Harmon MD, Murry T, Thun M. (2001), Cancer Statistics, CA Cancer J Clin., Vol. 51, 1-15

Hartman M., Baruch A., Ron I., Aderet Y., Yoeli M., Sagi-Assif O., Greenstein S., Stadler Y., Weiss M., Harness E., Yaakubovits M., Keydar I., Smorodinsky N.I., Wreschner D.H. (1999), MUC1 isoform specific monoclonal antibody 6E6/2 detects preferential expression of the novel MUC1/Y protein in breast and ovarian cancer, Int. J. Cancer, Vol. 19;82 (2), 256-267.

Jeschke U., Wiest I., Schumacher A.L, Kupka M., Rack B., Stahn R., Karsten U., Mayr D., Friese K. and Dian D. (2012), Determination of MUC1 in sera of ovarian cancer

patients and in sera of patients with benign changes of the ovaries with CA15-3, CA27.29, and PankoMab. Anticancer Research, Vol. 32, 2185-2190.

Joseph Z, Barnea I, Aylon Y, Gorivodsky M, Wreschner DH and Keydar I (2012), MUC1 gene over-expressed in breast cancer: structure and transcriptional activity of the MUC1 promoter and role of estrogen receptor alpha (ERα) in regulation of the MUC1 gene expression, Molecular Cancer,, Vol. 5:57, 1-14.

Kaur S, Momi N, Chakraborty S, Wagner DG, Horn AJ, Lele SM, Theodorescu D, Batra SK (2014), Altered expression of transmembrane mucins, MUC1 and MUC4, in bladder cancer: pathological implications in diagnosis, PLoS One. Vol. 26; 9(3), 1-11.

Klee G.G and Schreiber W.E. (2004), MUC1 gene–derived glycoprotein assays for monitoring breast cancer (CA 15-3, CA 27.29, BR) ; Are they measuring the same antigen?, Arch Pathol Lab Med—Vol. 128, 1131-1135.

Kufe DW (2013), MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches. Oncogene, Vol. 28; 32 (9), 1073-1081.

Laessig D., Nagel D., Heinemann V., Untch M., Kahlert S., Bauerfeind I. and Stieber P. (2007), Importance of CEA and CA 15-3 during disease progression in metastatic breast cancer patients, Anticancer Research Vol. 27, 1963-1968.

Lakshminarayanan V., Thompson P., Wolfert M.A., Buskas T., Bradley J.M., Pathangey L.B., Madsen C.S., Cohen P.A., Gendler S.J., Boons G.J. (2012), Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine, PNAS , Vol. 109: 1, 261–266.

Lloyd K. O., Burchell J., Kudryashov V., Yin B. W. T., and Taylor-Papadimitriou J. (1996), “Comparison of O-linked carbohydrate chains in MUC-1 mucin from normal breast epithelial cell lines and breast carcinoma cell lines: demonstration of simpler and fewer glycan chains in tumor cells, The Journal of Biological Chemistry, Vol. 271:52, 33325–33334.

Mukherjee P., Tinder T. L., Basu G. D., and Gendler S. J. (2005), MUC1 (CD227) interacts with lck tyrosine kinase in Jurkat lymphoma cells and normal T cells. Journal of Leukocyte Biology, Vol. 77, 90-99.

Obermair A., Schmid B.C., Packer L.M., Leodolter S., Birner P., Ward B.G., Crandon A.J., McGuckin M.A., Zeillinger R. (2002), Expression of MUC1 splice variants in benign and malignant ovarian tumours, Int. J. Cancer. Vol. 100(2), 166-171.

Oosterkamp H.M., Scheiner L., Stefanova M.C., Lloyd K.O. and Finstad C.L. (1997), Comparison of MUC-1 mucin expression in epithelial and non-epithelial cancer cell lines and demonstration of a new short variant form (MUC-1/Z). Int. J. Cancer, Vol. 72, 87–94.

Parry S, Silverman HS, McDermott K, Willis A (2001). Identification of MUC1 proteolytic cleavage sites in vivo, Biochem. Biophys. Res Commun, Vol. 283, 715-720.

Pedersen J.W., Gentry-Maharaj A., Nøstdal A., Fourkala E.O., Dawnay A., Burnell M., Zaikin A., Burchell J., Papadimitriou J.T., Clausen H., Jacobs I., Menon U., Wandall H.H. (2014), Cancer-associated autoantibodies to MUC1 and MUC4—A blinded case–control study of colorectal cancer in UK Collaborative Trial of Ovarian Cancer Screening. Int. J. Cancer, Vol. 134, 2180–2188.

Rodney C. Richie, John O. Swanson (2003), Breast Cancer: A review of the literature. J Insur Med., Vol. 35, 85–101.

Shindo Y., Hazama S., Maeda Y., Matsui H., Iida M., Suzuki N., Yoshimura K., Ueno T., Yoshino S., Sakai K, Suehiro Y., Yamasaki T., Hinoda Y and Oka M. (2014), Adoptive immunotherapy with MUC1-mRNA transfected dendritic cells and cytotoxic lymphocytes plus gemcitabine for unresectable pancreatic cancer. Journal of Translational Medicine, Vol.12:175, 1-14.

Sliwowska I., Kopczyński Z., Gazdecka S.G. (2006), Diagnostic value of measuring serum CA 15-3, TPA, and TPS in women with breast cancer, Postepy Hig Med Dosw. (online), Vol. 60, 295-299.

Suzuki Y., Sutoh M., Hatakeyama S., Mori K., Yamamoto H., Koie T., Saitoh H., Yamaya K., Funyu T., Habuchi T., Arai Y., Fukuda M., Ohyama C., Tsuboi S. (2012), MUC1 carrying core 2 O-glycans functions as a molecular shield against NK cell attack, promoting bladder tumor metastasis. Int J Oncol., Vol. 40(6), 1831–1838.

Takeuchi H., Kato K., Denda-Nagai K., Hanisch F. G., Clausen H., and Irimura T. (2002), The epitope recognized by the unique anti-MUC1 monoclonal antibody MY.1E12 involves sialylα2-3galactosylβ1-3N-acetylgalactosaminide linked to a distinct threonine residue in the MUC1 tandem repeat, Journal of Immunological Methods, Vol. 270:2,199–209.

Wang S, Chen X, Tang M.(2014), Quantitative assessment of the diagnostic role of MUC1 in pancreatic ductal adenocarcinoma, Tumour Biol. Vol. 35(9):9101-9109.